Brief: Akebia Therapeutics Inc - Akb-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027
12/01/2026 13:03
Jan 12 (Reuters) - Akebia Therapeutics Inc AKBA.O: AKEBIA THERAPEUTICS INC - AKB-097 PHASE 2 RARE KIDNEY DISEASE BASKET TRIAL SCHEDULED TO BEGIN IN 2H 2026 WITH INITIAL DATA EXPECTED IN 2027 Source text: ID:nGNX8XRBb8 Further company coverage: AKBA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule